KLIFO partner with TRI
Mar, 24, 2020
KLIFO partners with TRI to provide best-in-class clinical trial Risk Assessment and Management technology
KLIFO, a leading integrated drug development consultancy to biotech and pharmaceutical companies, announced today that it has entered a partnership with Triumph Research Intelligence (TRI), a global leader in Risk-Based Quality Management (RBQM) technology to use its OPRA RAM (Risk Assessment & Management) platform.
Copenhagen, Denmark – March 24, 2020 – KLIFO, a leading integrated drug development consultancy to biotech and pharmaceutical companies, announced today that it has entered a partnership with Triumph Research Intelligence (TRI), a global leader in Risk-Based Quality Management (RBQM) technology to use its OPRA RAM (Risk Assessment & Management) platform.
“We’re delighted to be partnering with TRI as its technology will enable us to deliver best-in-class clinical trial risk assessment and risk management for our sponsors,” said Klas Rådberg, VP Clinical Operations Solutions at KLIFO. “Having a fully validated solution means we can be confident in identifying and documenting potential study risks and see emerging trends, proactively manage risks, document our decisions, and produce auditable reports for our clients and the regulatory authorities. This will result in a huge improvement in trial quality management for our sponsors.”
TRI’s RBQM technology platform optimises trial quality by improving data reliability, patient safety and operational efficiency. Regulatory guidance requiring the adoption of RBQM has led to a rapid increase in demand for risk-based quality management solutions from CROs and sponsors.
“We’re very proud to be partnering with KLIFO. It is an industry leader with a global reputation for excellence,” said Duncan Hall, CEO and Founder of TRI. “KLIFO has worked hard to develop and implement robust processes for risk assessment and management, and will now benefit from the efficiency gains OPRA delivers over spreadsheet-based tools. We look forward to continuing to build on our partnership with KLIFO as OPRA is rolled out across their study portfolio.”
For more information please visit www.klifo.com and www.tritrials.com.
KLIFO is a leading integrated drug development consultancy with significant experience in partnering with biotech and pharmaceutical companies to advance their drug development projects. KLIFO offer multi-disciplinary consulting and operational solutions spanning all areas of regulatory affairs, clinical research, clinical trial supply, CMC development, pharmacovigilance, and the development of pharmaceutical and biotech products and medical devices.
TRI is the industry leading provider of Risk-Based Quality Management (RBQM) solutions for clinical trials. Based in Cambridge, UK, and Raleigh, North Carolina, USA, TRI was founded in 2013 by CEO Duncan Hall with the specific aim making RBQM simple and accessible for all clinical trials.